A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 24, 2018

Primary Completion Date

May 6, 2021

Study Completion Date

November 29, 2023

Conditions
Central Precocious Puberty (CPP)
Interventions
DRUG

Leuprolide Acetate (LA)

Administered intramuscularly as an injection

Trial Locations (18)

32207

Nemours Children's Health System /ID# 201331, Jacksonville

32806

Arnold Palmer Hospital /ID# 201624, Orlando

46202

Indiana University /ID# 200526, Indianapolis

64111

Children's Mercy Hospital/ID# 200221, Kansas City

76104

Cook Children's Med. Center /ID# 212937, Fort Worth

80045

Children's Hospital Colorado /ID# 201645, Aurora

80111

Pediatric Endocrine Associates /ID# 201089, Greenwood Village

92123

Rady Children's Hospital San Diego /ID# 202491, San Diego

98405

Multicare Institute for Research and Innovation /ID# 202188, Tacoma

90806-1651

Pediatric Endocrinology Associates /ID# 200629, Long Beach

30318-2508

Van Meter Pediatric Endocrinology /ID# 201688, Atlanta

83404-7596

Rocky Mountain Diabetes and Osteoporosis Center /ID# 209878, Idaho Falls

02114

Pediatric Endocrine Associates /ID# 202396, Boston

55455-1450

University of Minnesota /ID# 200508, Minneapolis

74135-2527

University of Oklahoma /ID# 200659, Tulsa

17033-2360

Penn State Hershey Medical Ctr /ID# 200287, Hershey

19104-4319

Children's Hospital of Philadelphia - Main /ID# 203846, Philadelphia

00935

Pediatric Endocrine Research Associates /ID# 200131, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY